Related references
Note: Only part of the references are listed.A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors
Nicola L. Steele et al.
CLINICAL CANCER RESEARCH (2008)
Phase I study of MGCD0103 given as a three-times-per-week oral dose in patients with advanced solid tumors
Lillian L. Siu et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Activity of the histone deacetylase inhibitor belinostat (PXD101) in preclinical models of prostate cancer
Xiaozhong Qian et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
The histone deacetylase inhibitor PXD101 synergises with 5-fluorouracil to inhibit colon cancer cell growth in vitro and in vivo
Anthony Tumber et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2007)
A study to determine the effects of food and multiple dosing on the pharmacokinetics of vorinostat given orally to patients with advanced cancer
Eric H. Rubin et al.
CLINICAL CANCER RESEARCH (2006)
Factors affecting the pharmacokinetic profile of MS-275, a novel histone deacetylase inhibitor, in patients with cancer
Milin R. Acharya et al.
INVESTIGATIONAL NEW DRUGS (2006)
Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian cancer studies
Xiaozhong Qian et al.
MOLECULAR CANCER THERAPEUTICS (2006)
Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer
WK Kelly et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma
QC Ryan et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Acetylation control of the retinoblastoma tumour-suppressor protein
HM Chan et al.
NATURE CELL BIOLOGY (2001)
Histone deacetylase inhibitors: Inducers of differentiation or apoptosis of transformed cells
PA Marks et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Share Paper
